[Possibilities of optimizing therapy in COVID-19 survivors with focal epilepsy]. / Vozmozhnosti optimizatsii terapii u patsientov s fokal'noi epilepsiei, perenesshikh COVID-19.
Zh Nevrol Psikhiatr Im S S Korsakova
; 123(3): 130-136, 2023.
Article
in Russian
| MEDLINE | ID: covidwho-2276728
ABSTRACT
OBJECTIVE:
To study the effect of phenosanoic acid therapy on the frequency of seizures, asthenia and quality of life of adult patients with focal epilepsy who had a new coronavirus infection caused by SARS-CoV-2. MATERIAL ANDMETHODS:
The data of 20 patients with focal epilepsy who suffered COVID-19 and received therapy with phenosanic acid (Dibufelon) were studied. The frequency of epileptic seizures, the severity of asthenia and the quality of life were evaluated according to clinical scales.RESULTS:
Significant decrease in the frequency of bilateral tonic-clonic seizures and focal seizures with loss of consciousness was recorded. There was a significant improvement in the quality of life. There was no significant dynamics of asthenia against the background of taking the drug phenosanic acid in patients.CONCLUSION:
The preparation of phenosanic acid can be an effective means of add-on therapy in patients with epilepsy who have undergone COVID-19.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Epilepsies, Partial
/
Epilepsy, Tonic-Clonic
/
Epilepsy
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
Limits:
Adult
/
Humans
Language:
Russian
Journal:
Zh Nevrol Psikhiatr Im S S Korsakova
Journal subject:
Neurology
/
Psychiatry
Year:
2023
Document Type:
Article
Affiliation country:
Jnevro2023123031130
Similar
MEDLINE
...
LILACS
LIS